SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?


To: JDN who wrote (707)7/15/1999 10:07:00 AM
From: DanZ  Read Replies (1) | Respond to of 5582
 
News:

GUM TECH ANNOUNCES CLINICAL RESEARCH ON NEW ZICAM(TM) COLD REMEDY
PR NEWSWIRE - July 15, 1999 09:24
PHOENIX, Jul 15, 1999 /PRNewswire via COMTEX/ -- Gum Tech International, Inc. (Nasdaq: GUMM) and BioDelivery Technologies, Inc. announced today that their joint venture, Gel Tech LLC, has begun additional clinical testing of the new ZICAM(TM) Cold Remedy.

Gel Tech is currently selling ZICAM(TM) to or filling orders for major retail chains, including Fry's, Albertsons, Rite Aid, Eckerd Drug, Genovese, King Kullen, American Drug Stores, Basha's, Kroger and Wal-Mart. Initial clinical research has indicated that use of ZICAM(TM) can reduce the duration of the common cold from 12 -- 14 days to 1 -- 3 days.

According to R. Steven Davidson, CEO of Gel Tech, "Scientists at twomajor universities have begun work on the next phase of clinical research concerning the efficacy of ZICAM(TM). The research will have three objectives: confirming ZICAM(TM)'s ability to significantly reduce the duration of the common cold; exploring ZICAM(TM)'s ability to act as a preventive measure against the common cold and its symptoms; and testing ZICAM(TM)'s ability to relieve symptoms caused by allergic reactions to common airborne allergens."

Davidson continued, "The independent studies will be conducted at multiple sites according to rigorous scientific protocols. The research on ZICAM(TM)'s therapeutic and preventive benefits will be conducted by inoculating patients with a common strain of rhinovirus."

Davidson concluded, "Baring unforeseen delays, we anticipate that the research will be completed by the end of October, 1999."

Gum Tech develops, manufactures, and distributes specialty chewing gum products designed to provide health benefits to consumers. The company partners with major food, pharmaceutical, or marketing companies to develop and manufacture gum products under contract manufacturing agreements and supports its own line of branded gums. Gum Tech operates one of the most advanced chewing gum manufacturing plants in the U.S. and is the only stainless steel gum manufacturing facility registered with the Food and Drug Administration to manufacture gum with over-the-counter drug products.

Gum Tech is located at 246 East Watkins Street, Phoenix, Arizona 85004. (Nasdaq: GUMM). E-mail: brown@gum-tech.com.

Gum Tech Forward-Looking Statement: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's anticipated growth in business and future results of operations. These forward-looking statements are based on the company's expectations and are subject to a number of risks and uncertainties, manyof which cannot be predicted or quantified and are beyond the company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from thecompany's expectations include lack of market acceptance for or uncertainties concerning the efficacy of ZICAM, delays in the development of clinical research onthe efficacy of ZICAM, less than anticipated demand for the company's chewing gum products, a decrease in the level of reorders from existing customers, financial difficulties encountered by one or more of the company's principal customers, difficulties in obtaining additional capital for marketing, research and development, and other expenses, the possibility of material charges incurred as a result of prior activities, aggressive pricing and marketing efforts by rival gum manufacturers, unavailability of third-party material products at reasonable prices, inventory obsolescence due to shifts in market demand, and material litigation involving product liabilities and consumers issues.

SOURCE Gum Tech International, Inc. (C) 1999 PR Newswire. All rights reserved. prnewswire.com -0-

CONTACT: Colleen Tiffany of The Logan Consulting Group, 716-244-7660,

for Gum Tech; or Brown Russell of Gum Tech International, 602-252-1617, or brown@gum-tech.com

WEB PAGE: gum-tech.com

GEOGRAPHY: Arizona

INDUSTRY CODE: MTC

SUBJECT CODE: JVN

PDT

News provided by COMTEX



To: JDN who wrote (707)7/16/1999 3:13:00 PM
From: Zeev Hed  Read Replies (1) | Respond to of 5582
 
JDN, I just read GUMM's new release and found it quite interesting, particularly this passage : "and is the only stainless steel gum manufacturing facility" (VBG), I presume next we will have gum made out of titanium (VBG). It just show how language, particularly English can be quite misleading...

As for your question on another thread, yes I looked and GUMM finances and could not find a floorlees. They have $2 MM of preferred convertible, but the conversion is not variable in time. The way I read it, the conversion rate is determined by the average price 20 days prior to a fixed conversion date (June 2, 2001, if memory serves). Around that date, you may find some "playing with the stock", but whether these games occur at $2/share or at $100/share, I have no way to determine.

By the way, this preferred and another $4 MM in additional borrowing is not enough money, IMHO, to get this show on the road in a real big way. These funds should barely suffice for the clinical studies to be undertaken between here and October. If sales let say get to $100 MM, they'll need a good $30 MM in additional funding to support working capital, IMHO.

I hope that helps.

Zeev